Objectives: This paper investigates the determinants of generic entry in the regulated Taiwanese prescription drug market, where physicians both prescribe and dispense drugs.
Methods: Using a sample of 29 ingredients and a population claim data set from 1997-2007, we employ the negative binomial regression to empirically examine the determinants of generic entry in Taiwan.
Results: This study finds that the lagged number of competitors, market size, and market share of large-scale medical providers affect generic entry.
Conclusions: The negative effect of large buyers on generic entry implies that rent-seeking behavior appears to create a barrier for generic manufacturers to enter into the Taiwanese prescription drug market.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.healthpol.2012.09.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Following the commodity risk assessment of plants grafted on from China, in which (Hemiptera: Diaspididae) was identified as a pest of possible concern, the European Commission requested the EFSA Panel on Plant Health to conduct a pest categorisation of for the territory of the European Union (EU). The origin of the scale insect is uncertain, with either South America or eastern Asia suggested as the native range. The geographic distribution of the species includes many countries of the continents of Africa, North and South America, Asia and Oceania.
View Article and Find Full Text PDFRedo mitral valve replacement with annular reconstruction of left atrial dissection following mitral valve replacement for infective endocarditis: a case report.
Gen Thorac Cardiovasc Surg Cases
January 2025
Department of Cardiovascular Surgery, Osaka General Medical Center, Osaka, 558-8558, Japan.
Background: Left atrial dissection is a rare and occasionally fatal complication of cardiac surgery and is defined as the creation of a false chamber through a tear in the mitral valve annulus extending into the left atrial wall. Some patients are asymptomatic, while others present with various symptoms, such as chest pain, dyspnea, and even cardiac arrest. Although there is no established management for left atrial dissection, surgery should be considered in patients with hemodynamic disruption.
View Article and Find Full Text PDF"Assessing the Effect of a Mobile Application on Cancer Risk Health Literacy: A Cross-Sectional Study Design".
Appl Clin Inform
January 2025
Radiotherapy, CHU de Liège, Liège, Belgium.
Background: The "Cancer Risk Calculator" mobile application aims to inform patients about their personal risks of cancer and their risk factors influencingsaid risks. The present analysis examines the responses to a questionnaire submitted by oncology patients treated with radiotherapy or their family members.
Objective: The primary objective was to determine the effectof the app on the user's awareness and potential habit changes related to cancer risk.
Cathepsin-D and outcomes in peripartum cardiomyopathy: Results from IPAC.
Am Heart J Plus
January 2025
University of Pittsburgh Medical Center, Pittsburgh, PA, United States of America.
Objective: Evaluate the relationship of cathepsin-D (CD) on disease severity and clinical outcomes for women with peripartum cardiomyopathy.
Background: Cathepsin-D is a protease released during oxidative stress that cleaves prolactin (PRL) generating a 16 kDa fragment that is pro-apoptotic, anti-angiogenic, and has been implicated in the pathogenesis of peripartum cardiomyopathy (PPCM).
Methods: In 99 women with newly diagnosed PPCM enrolled in the Investigation in Pregnancy Associated Cardiomyopathy (IPAC) study, CD levels were assessed by ELISA from serum obtained at study entry.
Patient experience with acute hepatic porphyria before and after long-term givosiran treatment in a qualitative interview study.
Mol Genet Metab Rep
March 2025
Alnylam Pharmaceuticals, Maidenhead, UK.
Background: Acute hepatic porphyria (AHP) is characterized by debilitating and potentially life-threatening neurovisceral attacks, possible chronic symptoms, and long-term complications. In a phase 1/2 open-label extension (OLE) study and the phase 3 ENVISION study, givosiran led to sustained improvement in annualized attack rate and quality of life (QOL) measures. To capture the patient experience of symptoms and impacts of AHP, and any changes experienced during treatment with givosiran, qualitative interviews were conducted with study participants.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!